Article: Erlotinib as salvage treatment after failure to first-line Gefitinib in non-small cell lung cancer

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleErlotinib as salvage treatment after failure to first-line Gefitinib in non-small cell lung cancer
AuthorsWong, MK2
Lo, AI1
Lam, B2
Lam, WK2
Ip, MS2
Ho, JC2
KeywordsAsians
Disease control rate
Epidermal growth factor receptor tyrosine kinase inhibitors
Erlotinib
Gefitinib
Non-small cell lung cancer
Issue Date2010
PublisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
CitationCancer Chemotherapy And Pharmacology, 2010, v. 65 n. 6, p. 1023-1028 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s00280-009-1107-5
AbstractPurpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. The purpose of this study is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. Method Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as firstline treatment and subsequent salvage treatment with erlotinib. Results A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 12 (57.1%) patients with salvage erlotinib. There was an association between the disease control with gefitinib and erlotinib (p = 0.031). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. Conclusion For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib. © Springer-Verlag 2009.
ISSN0344-5704
2011 Impact Factor: 2.833
2011 SCImago Journal Rankings: 0.246
DOIhttp://dx.doi.org/10.1007/s00280-009-1107-5
PubMed Central IDPMC2946542
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorWong, MK
dc.contributor.authorLo, AI
dc.contributor.authorLam, B
dc.contributor.authorLam, WK
dc.contributor.authorIp, MS
dc.contributor.authorHo, JC
dc.date.accessioned2010-10-18T06:18:55Z
dc.date.available2010-10-18T06:18:55Z
dc.date.issued2010
dc.description.abstractPurpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer (NSCLC). Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been recently shown to be effective as a first-line treatment in Asian patients with advanced NSCLC, especially for those with favourable clinical features such as female, non-smoker and adenocarcinoma. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment. The purpose of this study is to evaluate the efficacy of erlotinib, another EGFR-TKI, after failed first-line use of gefitinib. Method Retrospective review of NSCLC patients with favourable clinical features who received gefitinib as firstline treatment and subsequent salvage treatment with erlotinib. Results A total of 21 patients with NSCLC were included in the study. Among them, 18 (85.7%) patients had disease control with gefitinib and 12 (57.1%) patients with salvage erlotinib. There was an association between the disease control with gefitinib and erlotinib (p = 0.031). The disease control rate of erlotinib was independent of the chemotherapy use between the two EGFR-TKIs. Conclusion For NSCLC patients with favourable clinical features, erlotinib was effective in those who had prior disease control with first-line gefitinib. © Springer-Verlag 2009.
dc.description.naturepublished_or_final_version
dc.description.otherSpringer Open Choice, 01 Dec 2010
dc.identifier.citationCancer Chemotherapy And Pharmacology, 2010, v. 65 n. 6, p. 1023-1028 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s00280-009-1107-5
dc.identifier.citeulike5541820
dc.identifier.doihttp://dx.doi.org/10.1007/s00280-009-1107-5
dc.identifier.eissn1432-0843
dc.identifier.epage1028
dc.identifier.hkuros172598
dc.identifier.isiWOS:000275632400003
dc.identifier.issn0344-5704
2011 Impact Factor: 2.833
2011 SCImago Journal Rankings: 0.246
dc.identifier.issue6
dc.identifier.openurl
dc.identifier.pmcidPMC2946542
dc.identifier.pmid19680652
dc.identifier.scopuseid_2-s2.0-77951895524
dc.identifier.spage1023
dc.identifier.urihttp://hdl.handle.net/10722/123997
dc.identifier.volume65
dc.languageeng
dc.publisherSpringer. The Journal's web site is located at http://www.springer.com/medicine/oncology/journal/280
dc.publisher.placeGermany
dc.relation.ispartofCancer Chemotherapy and Pharmacology
dc.relation.referencesReferences in Scopus
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.rightsSpringer-Verlag
dc.subject.meshAged
dc.subject.meshCarcinoma, Non-Small-Cell Lung - drug therapy
dc.subject.meshLung Neoplasms - drug therapy
dc.subject.meshQuinazolines - therapeutic use
dc.subject.meshSalvage Therapy - methods
dc.subjectAsians
dc.subjectDisease control rate
dc.subjectEpidermal growth factor receptor tyrosine kinase inhibitors
dc.subjectErlotinib
dc.subjectGefitinib
dc.subjectNon-small cell lung cancer
dc.titleErlotinib as salvage treatment after failure to first-line Gefitinib in non-small cell lung cancer
dc.typeArticle
Author Affiliations
  1. Centro Hospital Conde de Sao Januario
  2. The University of Hong Kong